Global Cancer Pain Therapeutics Market 2015-2019 Description
TechNavio - Infiniti Research Ltd.
Global Cancer Pain Therapeutics Market 2015-2019
About Cancer Pain Therapeutics
Cancer pain can be acute or chronic, depending on its stages and types. Cancer pain is caused by the tumor pressing against bones, nerves, or other organs in an individual's body. Pain control is imperative not only for people who have advanced cancer but also for those whose condition remains stable for years. Pharmaceutical interventions such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvant pain medications are used to treat cancer pain.
Technavio’s analysts forecast the global cancer pain therapeutics market to grow at a CAGR of 9.08% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global cancer pain therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of cancer pain.
The market is divided into the following segments based on region:
- Americas: The US, Canada, Mexico, and Brazil
- EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
- APAC: Japan, China, Australia, Singapore, South Korea, and India
Technavio's report, Global Cancer Pain Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors - BioDelivery Sciences
- ProStrakan Group
- Teva Pharmaceuticals
- Yamaha
Other prominent vendors- Daiichi Sankyo
- Eli-lilly
- Galena Biopharma
- Grunenthal Group
- GW Pharmaceuticals
- Hospira
- Johnson & Johnson
- Meda Pharmaceuticals
- Orexo
- Sanofi
- Sorrento Therapeutics
- WEX Pharmaceuticals
Market driver - Unmet medical needs
- For a full, detailed list, view our report
Market challenge - Off-label drug use
- For a full, detailed list, view our report
Market trend - Increase in awareness
- For a full, detailed list, view our report
Key questions answered in this report - What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Press Release
Technavio Announces the Publication of its Research Report – Global Cancer Pain Therapeutics Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Cancer Pain Therapeutics Market: BioDelivery Sciences, ProStrakan Group and Teva Pharmaceuticals
Other Prominent Vendors in the market are: Daiichi Sankyo, Eli-lilly, Galena Biopharma, Grunenthal Group, GW Pharmaceuticals, Hospira, Johnson & Johnson, Meda Pharmaceuticals, Orexo, Sanofi, Sorrento Therapeutics, and WEX Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “At present, the cancer pain therapeutics market has Teva Pharmaceuticals, BioDelivery Sciences, and ProStrakan Group as the key players. Teva Pharmaceutical's Actiq and Fentora; and ProStrakan's Abstral and Lazanda compete directly with BioDelivery Sciences' Onsolis. To overcome the severe competition being posed, the key players and other vendors have started differentiating their drugs in an attempt to increase profits and avoid price competition.”
According to the report, the major driving factor for the global cancer pain therapeutics market is the high unmet need for appropriate drugs in the market.
Further, the report states that the use of off-label drugs is another important challenge for the market.
Companies Mentioned
BioDelivery Sciences, ProStrakan Group, Teva Pharmaceuticals, Daiichi Sankyo, Eli-lilly, Galena Biopharma, Grunenthal Group, GW Pharmaceuticals, Hospira, Johnson & Johnson, Meda Pharmaceuticals, Orexo, Sanofi, Sorrento Therapeutics, WEX Pharmaceuticals.
